Global Antibody Drug Conjugate Contract Market Demand Is Anticipated To Be Valued At US$ 9.2 Billion In 2022


Newly-released Antibody Drug Conjugates Contract Market industry analysis report by Fact.MR shows that global sales of the Antibody Drug Conjugates Contract Market in 2021 were held at US$ 8.1 Bn. With a CAGR of 15.5 %, the projected market growth during the period 2022-2032 is expected to be slightly higher than the historical growth which stood at 12.7%.

The Antibody Drug Conjugates Contract Market is accounted to give an absolute dollar opportunity growth of nearly US$ 29.7 Bn during 2022 – 2032. Myeloma is expected to be the highest revenue-generating condition type.

Market Segments Covered in Antibody Drug Conjugates Contract Market Industry Analysis

  • By Condition Type

    • Myeloma
    • Lymphoma
    • Breast Cancer
    • Other Condition Types
  • By Application

    • Cleavable Linker
    • Non-cleavable Linker
  • By Region

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Competitive Analysis

The contract manufacturing industry for antibody drug conjugates is very competitive, with numerous prominent companies. Pantheon, Corden Pharma, Abbvie Inc, Novasep, Merck Lonza group, Cambrex Corporation, Recipharm, Thermo Fisher Scientific, Inc, and Sterling Pharma Solutions are some of the market leaders.

Companies are making significant efforts and capital investments to increase their skills and, as a result, enhance their respective service lineups in order to acquire a competitive advantage. Some companies have built new facilities dedicated to the production of highly powerful chemicals. Various agreements between medication inventors and ADC makers have also been observed in the field.

Some of the recent developments of Antibody Drug Conjugates Contract Market providers are as follows:

  • In January 2022, Recipharm announced the purchase of GenIbet to expand its biologics platform.
  • In August 2021, Recipharm announced that it has opened a new laboratory to boost its analytical services.
  • In July 2021, Lonza Group has extended its relationship with a large biopharmaceutical sector client for the supply of an antibody-drug conjugate against hard-to-treat malignancies.
  • In September 2020, Merck announced a EUR 59 million expansion of its ADC manufacturing capabilities at its Wisconsin site. This investment is likely to enable the large-scale production of increasingly effective chemicals for cancer therapy.

Similarly, recent developments related to companies offering Antibody Drug Conjugates Contract Market have been tracked by the team at Fact.MR, which are available in the full report.

Leave a Reply

Related Posts